Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Summary The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-12, Vol.17 (12), p.e542-e551
Hauptverfasser:	Gibney, Geoffrey T, Dr, Weiner, Louis M, Prof, Atkins, Michael B, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - analysis B7-H1 Antigen - antagonists & inhibitors Biomarkers Biomarkers - analysis Bladder cancer Cancer therapies Cell Cycle Checkpoints Gene expression Genotype & phenotype Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Immunotherapy Immunotherapy - methods Interferon Lung cancer Lymphocytes Lymphocytes, Tumor-Infiltrating - immunology Melanoma Metastasis Mutation Neoplasms - therapy Patients Pharmaceutical industry T cell receptors Tumor Microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!